Advertisement
Screener

Mirum Pharmaceuticals, Inc. (MIRM) Increase (Decrease) in Prepaid Expense and Other Assets

2.8 / 5 stars · 68/120 Roast Me

Mirum Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense and Other Assets

Mirum Pharmaceuticals, Inc. (MIRM) reported Increase (Decrease) in Prepaid Expense and Other Assets of $7.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05

  • Mirum Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.08M, a 73.46% decline year-over-year.
  • Mirum Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $6.63M, a 118.88% increase year-over-year.
  • Mirum Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$5.99M.
  • Mirum Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $4.63M, a 33.60% increase year-over-year.
  • Mirum Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $5.76M, a 577.97% increase from fiscal 2024.
  • Mirum Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $849.00K, a 76.42% decline from fiscal 2023.
  • Mirum Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $3.60M, a 2.07% decline from fiscal 2022.
  • Mirum Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $3.68M, a 8.31% decline from fiscal 2021.
Period endIncrease (Decrease) in Prepaid Expense and Other Assets 3 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 monthIncrease (Decrease) in Prepaid Expense and Other Assets 8 monthIncrease (Decrease) in Prepaid Expense and Other Assets 9 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 month
2026-06-30$1.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$7.71M
10-Q · filed 2026-08-05
$1.72M
derived: sum of 3 quarters · filed 2026-08-05
$6.36M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$6.63M
10-Q · filed 2026-05-06
$640.00K
derived: sum of 2 quarters · filed 2026-05-06
$5.27M
derived: sum of 3 quarters · filed 2026-05-06
$9.36M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$5.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$1.36M
derived: sum of 2 quarters · filed 2026-02-25
$2.73M
derived: sum of 3 quarters · filed 2026-08-05
$5.76M
10-K · filed 2026-02-25
2025-09-30$4.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$8.72M
derived: sum of 2 quarters · filed 2026-08-05
$11.75M
10-Q · filed 2025-11-04
$11.47M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$4.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$7.11M
10-Q · filed 2026-08-05
$6.84M
derived: sum of 3 quarters · filed 2026-08-05
$10.31M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$3.03M
10-Q · filed 2026-05-06
$2.76M
derived: sum of 2 quarters · filed 2026-05-06
$6.22M
derived: sum of 3 quarters · filed 2026-05-06
$4.80M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31-$273.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$3.19M
derived: sum of 2 quarters · filed 2026-02-25
$1.77M
derived: sum of 3 quarters · filed 2026-02-25
$849.00K
10-K · filed 2026-02-25
2024-09-30$3.47M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$2.04M
derived: sum of 2 quarters · filed 2025-11-04
$1.12M
10-Q · filed 2025-11-04
$1.27M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30-$1.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
-$2.35M
10-Q · filed 2025-08-06
-$2.19M
derived: sum of 3 quarters · filed 2026-02-25
$473.00K
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31-$918.00K
10-Q · filed 2025-05-07
-$765.00K
derived: sum of 2 quarters · filed 2026-02-25
$1.90M
derived: sum of 3 quarters · filed 2026-02-25
$2.64M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$153.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$2.82M
derived: sum of 2 quarters · filed 2026-02-25
$3.56M
derived: sum of 3 quarters · filed 2026-02-25
$3.60M
10-K · filed 2026-02-25
2023-09-30$2.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$3.41M
derived: sum of 2 quarters · filed 2024-11-12
$3.45M
10-Q · filed 2024-11-12
$5.46M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$742.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
$782.00K
10-Q · filed 2024-08-07
$2.80M
derived: sum of 3 quarters · filed 2025-02-26
$5.95M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$40.00K
10-Q · filed 2024-05-08
$2.06M
derived: sum of 2 quarters · filed 2025-02-26
$5.21M
derived: sum of 3 quarters · filed 2025-02-26
$3.08M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$2.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$5.17M
derived: sum of 2 quarters · filed 2025-02-26
$3.04M
derived: sum of 3 quarters · filed 2025-02-26
$3.68M
10-K · filed 2025-02-26
2022-09-30$3.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
$1.02M
derived: sum of 2 quarters · filed 2023-11-02
$1.66M
10-Q · filed 2023-11-02
$3.43M
derived: sum of 4 quarters · filed 2024-03-15
2022-06-30-$2.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
-$1.49M
10-Q · filed 2023-08-07
$275.00K
derived: sum of 3 quarters · filed 2024-03-15
$2.62M
derived: sum of 4 quarters · filed 2024-03-15
2022-03-31$637.00K
10-Q · filed 2023-05-04
$2.40M
derived: sum of 2 quarters · filed 2024-03-15
$4.75M
derived: sum of 3 quarters · filed 2024-03-15
$4.53M
derived: sum of 4 quarters · filed 2024-03-15
2021-12-31$1.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15
$4.11M
derived: sum of 2 quarters · filed 2024-03-15
$3.90M
derived: sum of 3 quarters · filed 2024-03-15
$4.01M
10-K · filed 2024-03-15
2021-09-30$2.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$2.13M
derived: sum of 2 quarters · filed 2022-11-09
$2.24M
10-Q · filed 2022-11-09
$2.37M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30-$215.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$103.00K
10-Q · filed 2022-08-04
$25.00K
derived: sum of 3 quarters · filed 2022-08-04
$1.69M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31$112.00K
10-Q · filed 2022-05-05
$240.00K
derived: sum of 2 quarters · filed 2022-05-05
$1.90M
derived: sum of 3 quarters · filed 2022-05-05
$1.78M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31$128.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09
$1.79M
derived: sum of 2 quarters · filed 2022-03-09
$1.67M
derived: sum of 3 quarters · filed 2022-03-09
$1.83M
10-K · filed 2022-03-09
2020-09-30$1.66M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$1.54M
derived: sum of 2 quarters · filed 2021-11-15
$1.70M
10-Q · filed 2021-11-15
$1.34M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30-$122.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$36.00K
10-Q · filed 2021-08-05
-$319.00K
derived: sum of 3 quarters · filed 2021-08-05
$2.07M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$158.00K
10-Q · filed 2021-05-06
-$197.00K
derived: sum of 2 quarters · filed 2021-05-06
$2.19M
derived: sum of 3 quarters · filed 2021-05-06
$2.60M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31-$355.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09
$2.04M
derived: sum of 2 quarters · filed 2021-03-09
$2.44M
derived: sum of 3 quarters · filed 2021-03-09
$2.69M
10-K · filed 2021-03-09
2019-09-30$2.39M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
$2.79M
derived: sum of 2 quarters · filed 2020-11-12
$3.05M
10-Q · filed 2020-11-12
2019-06-30$403.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
$654.00K
10-Q · filed 2020-08-06
2019-03-31$251.00K
10-Q · filed 2020-05-07
2018-12-31$12.00K
10-K · filed 2020-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Liquidia Corp (LQDA)United States$6.347B51.23
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
Erasca, Inc. (ERAS)United States$5.073B-19.96
Veradermics, Inc (MANE)United States$4.839B